2. Academic Validation
  3. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

  • Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82. doi: 10.1128/AAC.00194-12.
Louis D Saravolatz 1,  Joan Pawlak,  Leonard Johnson,  Hector Bonilla,  Louis D Saravolatz 2nd,  Mohamad G Fakih,  Anders Fugelli,  Wenche Marie Olsen
Affiliations

Affiliation

  • 1 St. John Hospital and Medical Center, Detroit, Michigan, USA. louis.saravolatz@stjohn.org
PMID: 22585222 DOI: 10.1128/AAC.00194-12
Abstract

LTX-109 and eight Other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin and strains with decreased susceptibility to daptomycin and linezolid, by microdilution tests to determine MICs. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus. This activity was not influenced by resistance to Other antistaphylococcal agents.

Figures
Products